NCT02180269View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-54861911 (25 mg)

Single oral dose of JNJ-54861911, 25 mg on Day 1.

DRUG

JNJ-54861911 (50 mg)

Single oral dose of JNJ-54861911, 50 mg on Day 1.

DRUG

JNJ-54861911 (100 mg)

Single oral dose of JNJ-54861911, 100 mg on Day 1.

DRUG

Placebo

Single oral dose of placebo matched to JNJ-54861911 on Day 1.

Trial Locations (1)

Unknown

Fukuoka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT02180269 - A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants | Biotech Hunter | Biotech Hunter